Insider Buying: Nutex Health (NASDAQ:NUTX) Director Purchases $14,034.00 in Stock

Nutex Health Inc. (NASDAQ:NUTX) Director Frank Jaumot purchased 150 shares of Nutex Health stock in a transaction on Friday, March 20th. The shares were acquired at an average cost of $93.56 per share, with a total value of $14,034.00. Following the completion of the transaction, the director directly owned 150 shares in the company, valued at $14,034. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Nutex Health Stock Performance

Shares of NASDAQ NUTX opened at $100.38 on Thursday. The company has a 50 day simple moving average of $116.07 and a two-hundred day simple moving average of $125.28. The stock has a market cap of $699.65 million, a price-to-earnings ratio of 11.18 and a beta of 0.03. The company has a current ratio of 3.41, a quick ratio of 3.39 and a debt-to-equity ratio of 0.70. Nutex Health Inc. has a 12 month low of $45.88 and a 12 month high of $193.07.

Nutex Health (NASDAQ:NUTX) last released its quarterly earnings data on Thursday, March 5th. The company reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). Nutex Health had a return on equity of 17.67% and a net margin of 7.34%.The business had revenue of $151.68 million during the quarter, compared to analyst estimates of $258.82 million.

Analysts Set New Price Targets

Several equities research analysts have weighed in on NUTX shares. Wall Street Zen downgraded Nutex Health from a “strong-buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “hold (c)” rating on shares of Nutex Health in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Nutex Health presently has a consensus rating of “Moderate Buy” and an average target price of $252.50.

Institutional Trading of Nutex Health

Institutional investors have recently bought and sold shares of the business. Islay Capital Management LLC purchased a new stake in shares of Nutex Health in the fourth quarter valued at approximately $34,000. State of Alaska Department of Revenue purchased a new position in shares of Nutex Health during the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets lifted its position in shares of Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock valued at $40,000 after buying an additional 290 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in Nutex Health in the 2nd quarter valued at $44,000. Finally, Royal Bank of Canada grew its stake in Nutex Health by 752.4% in the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after acquiring an additional 316 shares during the period. 5.32% of the stock is owned by institutional investors and hedge funds.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.